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Abstract
Background: Disruption of the nucleolus often leads to activation of the p53 tumor suppressor pathway through inhibition
of MDM2 that is mediated by a limited set of ribosomal proteins including RPL11 and RPL5. The effects of ribosomal protein
loss in cultured mammalian cells have not been thoroughly investigated. Here we characterize the cellular stress response
caused by depletion of ribosomal protein S9 (RPS9).
Methodology/Principal Findings: Depletion of RPS9 impaired production of 18S ribosomal RNA and induced p53 activity. It
promoted p53-dependent morphological differentiation of U343MGa Cl2:6 glioma cells as evidenced by intensified
expression of glial fibrillary acidic protein and profound changes in cell shape. U2OS osteosarcoma cells displayed a limited
senescence response with increased expression of DNA damage response markers, whereas HeLa cervical carcinoma cells
underwent cell death by apoptosis. Knockdown of RPL11 impaired p53-dependent phenotypes in the different RPS9
depleted cell cultures. Importantly, knockdown of RPS9 or RPL11 also markedly inhibited cell proliferation through p53-
independent mechanisms. RPL11 binding to MDM2 was retained despite decreased levels of RPL11 protein following
nucleolar stress. In these settings, RPL11 was critical for maintaining p53 protein stability but was not strictly required for
p53 protein synthesis.
Conclusions: p53 plays an important role in the initial restriction of cell proliferation that occurs in response to decreased
level of RPS9. Our results do not exclude the possibility that other nucleolar stress sensing molecules act upstream or in
parallel to RPL11 to activate p53. Inhibiting the expression of certain ribosomal proteins, such as RPS9, could be one
efficient way to reinitiate differentiation processes or to induce senescence or apoptosis in rapidly proliferating tumor cells.
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Introduction
Ribosome biogenesis is a highly complex process in which
hundreds of different proteins co-operate in ribosomal RNA
(rRNA) synthesis, processing, ribosome subunit assembly and
transport [1]. Nucleoli are the actual sites for ribosome biogenesis
but these structures have also been implicated in other cellular
processes such as control of the cell cycle, viral replication,
mitogenic signaling, nuclear export of p53, and stem cell
differentiation, reviewed in references [1]–[4]. Over the last
decade, the connection between the tumor suppressor protein p53,
the nucleolus, and ribosome biogenesis has become well
established. Expression of dominant negative mutants of the
nucleolar protein Bop1 resulted in defects in rRNA processing
triggering p53 induced cell cycle arrest [5]. p53 often becomes
activated after silencing of nucleolar or ribosomal proteins (r-
proteins), and examples include RPL23 [6], RPS6 [7], nucleos-
temin, [8] and TIF1A [9]. Moreover, inhibitors of rRNA synthesis
or processing such as actinomycin D and 5-fluorouracil also
activate p53 [10]. Collectively these conditions are referred to as
nucleolar or ribosomal stress. Mounting evidence from a number
of mouse models proves the existence of this p53-dependent
checkpoint in vivo. One mouse model revealed that ribosome
biogenesis is impaired after conditional deletion of one allele of
Rps6 [11]. Interestingly, the embryonic lethality that occurred
during gastrulation in these Rps6
+/2 embryos was caused by a
p53-dependent checkpoint rather than a general decrease in
translational capacity [11]. Rpl22 deficiency selectively arrested
development of alpha/beta-lineage T cells, a response mediated
by activation of p53 [12]. In turn, p53 loss restored the
development of Rpl22-deficient thymocytes.
Mutations have been found in different r-proteins in patients
suffering from a syndrome known as Diamond-Blackfan anemia
(DBA, MIM #105650), characterized by defective erythropoiesis,
congenital anomalies and an increased risk of cancer [13], [14].
The gene RPS19 is frequently mutated in DBA [15], but mutations
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and RPS7 [16], [17]. Animal models of DBA have been created in
mice and zebrafish [18], [19]. It was found that loss of Rps19 is
embryonic lethal [20]. Rps19 deficiency impairs ribosomal
biogenesis and activates p53 in zebrafish, and the suppression of
p53 and deltaNp63 can alleviate the Rps19-deficient phenotype in
this model [18]. Loss of other r-proteins in zebrafish, such as Rps8,
Rps11, and Rps18 also triggered a p53 response [18]. The role of
p53 in DBA remains unclear but it is notable that mice bearing
mutations in RpS19 and Rps20 have low erythrocyte counts that
can be restored by p53 deficiency [21].
How is p53 activated following nucleolar stress? Several groups
have shown that r-proteins (RPL11, RPL5, RPL23 and RPS7) are
released from the nucleolus during stress and then bind MDM2
thereby activating p53 [6], [22]–[29]. It was subsequently found
that increased translation of 59 terminal oligopyrimidine (TOP)
mRNAs, including that of RPL11, occurs in response to disrupted
40S ribosomal subunit biogenesis thereby leading to an increase in
RPL11 production [30]. Indeed, following loss of RPS6 or RPL24
the p53 tumor suppressor is activated in a manner dependent on
RPL11 [30], [31]. While decreased expression of some r-proteins
can activate p53 as part of a cellular stress response, it is also
evident that some other r-proteins have direct and more specific
roles in p53 mRNA translation. Haploinsufficiency of a subset of r-
proteins in zebrafish is linked to the development of malignant
peripheral nerve sheath tumors [32]. Interestingly, these nerve
sheath tumors fail to produce p53 protein, despite presence of p53
mRNA [33]. Moreover, RPL26 plays a role in enhancing p53
mRNA translation during the DNA damage response by direct
interactions with both MDM2 protein and p53 mRNA [34].
Hence, r-proteins have more dynamic roles in regulating the p53
tumor suppressor pathway than was previously thought, reviewed
in [35]–[37].
Recently, RPS9 was identified as a novel B23 (NPM/
nucleophosmin) interacting protein [38]. Decreased levels of
RPS9 were associated with accumulation of cells in G1/(G0) and
p21 induction in U2OS osteosarcoma cells [38]. Here we set out
to further investigate the different cellular stress responses caused
by loss of RPS9. Depletion of RPS9 provoked a rapid loss of the
nucleolar protein pool, impaired production of mature 18S
ribosomal RNA and activation of the p53 tumor suppressor
pathway. We found that the combination of a defective ribosome
biogenesis pathway and p53 activation resulted in unexpectedly
strong anti-proliferative responses in human tumor cell lines in
that they underwent senescence, differentiation, or apoptosis
following depletion of RPS9.
Results
Rapid Depletion of Nucleolar RPS9 Following siRNA
Transfection
To fuse r-proteins with GFP has proved a useful tool to better
visualize the localization and turnover of r-proteins in human cells
[39], [40]. U2OS cells expressing RPS9-GFP had been previously
established [38]. In these cells the RPS9-GFP fusion protein was
localized to the nucleolus and the cytoplasm. To better understand
the dynamics of RPS9 in relation to knockdown phenotypes, we
used RPS9-GFP U2OS cells combined with RNA interference to
visualize knockdown of RPS9 in living cells (Figure 1A).
Transfection of U2OS cells with RPS9 siRNA indicated a rapid
turnover of nucleolar RPS9-GFP. Already 24 hours after trans-
fection a majority of the cells showed a striking loss of nucleolar
RPS9-GFP (Figure 1B). At 72 hours post-transfection, most cells
had a GFP signal detectable only in the cytoplasm. Using
immunoblotting RPS9-GFP was detected as a single band of the
expected size that was decreased upon siRNA transfection with
two different RPS9 siRNAs #1 and #2, whereas knockdown with
oligo #0 was ineffective when compared to the control siRNA,
siCtrl (Figure 1C). The pool of cytoplasmic RPS9-GFP protein
remained for several days in agreement with the known stability of
mammalian cytoplasmic ribosomes. We have been unable to
completely deplete cells of cytoplasmic GFP reactivity which could
be due to the fact that silencing with siRNA is not 100%, or that a
total loss of RPS9 is not compatible with sustained cell
proliferation. To further confirm the cellular distribution of
RPS9, U2OS cells were stained with an antibody raised against
human RPS9, as described [38], and an identical nucleolar and
cytoplasmic staining was observed. The nucleolar pool of
endogenous RPS9 could be rapidly and efficiently silenced in
U2OS cells similar to that of RPS9-GFP (Figure S1A), and this
was confirmed by immunoblotting (Figure S1B). In summary, we
obtained a complete and specific depletion of nucleolar RPS9
using siRNA.
Induction of a Limited Senescence Response in U2OS
Cells
Disruption of the nucleolus is often seen following exposure of
cells to a variety of chemical and physical agents that inhibit
transcription or rRNA processing [10]. A close inspection of
nucleoli revealed that they remained intact in response to
treatment with siRPS9, in agreement with studies on RPS6 [11],
[30]. But, we noted that nucleoli in RPS9 depleted U2OS cells
were more contrasted, round, and phase-dense than in siCtrl
Figure 1. Nucleolar and cytoplasmic localization of RPS9-GFP.
(A) Efficiency of RPS9-GFP knockdown in U2OS cells that stably express
RPS9-GFP when using three different siRNAs targeting human RPS9.
Photos of cells expressing RPS9-GFP were taken after 48 hours. (B)
Percentage of U2OS cells expressing detectable RPS9-GFP in the
nucleolus at various time points after transfection of RPS9-1 siRNA or
siCtrl. (C) Equal number of cells from experiment in (A) was collected
and whole cell extracts prepared in buffer containing 2% SDS. Protein
lysates were separated by SDS-PAGE and immunoblotted with
antibodies specific for EGFP, PCNA, b-actin, and RPL11 as indicated in
the figure.
doi:10.1371/journal.pone.0009578.g001
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(Figure S2A). Nucleolar dense fibrillar centers were in a few cells
re-localized to the periphery of the nucleolus as revealed by
staining for fibrillarin, a marker of the dense fibrillar compartment
of the nucleolus. These nucleoli resembled the enlarged nucleoli
observed in U2OS cells depleted of nucleostemin [8], a nucleolar
protein involved in ribosome biogenesis [41].
Knockdown of RPS9 induced accumulation of cells in G1 and
increased the levels of p21 in U2OS cells [38]. A more careful
examination of the cells revealed that a fraction displayed a rather
‘‘severe’’ phenotype resembling senescence with a grossly expand-
ing cytoplasm leading us to further investigate this particular
response (Figure 2A). Depletion of RPS9 induced an increase in
the number of c-H2A.X positive cells and cells with nuclear foci of
phospho-ATM/ATR substrate proteins (Figure 2B and C).
Analysis revealed an increase of senescence associated b-
galactosidase–positive (SA-b-gal) U2OS cells from 0.4% positive
cells in siCtrl cells, to 7% in siRPS9 transfected cells (Figure 2D).
To formally demonstrate the role of p53 in mediating inhibition
of U2OS cell proliferation we co-depleted p53 and RPS9 resulting
in a reversion of the senescence phenotype (Figure 2A and D). In
addition, RPL11, p53 or p21 co-depletion in siRPS9-treated cells
increased BrdU incorporation in these cultures at 24 hours post-
transfection (Figure 2E), coupled with a rescue of the senescence-like
morphology (Figure S3). We wanted to know how this ‘‘escape’’
from G1 arrest related to cell growth in the longer run, so we also
investigated cell proliferation at a later time point. We found
that siRPS9 treated cultures had grown 36% (69.2) whereas
siRPS9+sip53 treated cells had grown 52% (66.5) compared to
siCtrl as evaluated 72 hours post-transfection (Figure 2F). Silencing
of RPL11 restored cell count to the level seen in cells co-transfected
with siRPS9 and sip53, but it could not restore the cell number to
that seen in siCtrl cultures, hence siRPS9+siRPL11 treated cells had
grown 56% (64.4) compared to siCtrl (Figure 2F). This indicated
that silencing of RPS9 or RPL11 also induced suppression of cell
proliferation in a p53-independent manner. This was confirmed by
depleting RPS9 in matched WI38 and WI38-E6 fibroblasts as well
as in SAOS2 osteosarcoma cells lacking p53 (Figure S1D).
Regulation of the p53 Response Triggered by RPS9 Loss
in U2OS Cells
The decreased expression of RPS9 in U2OS cells did not
markedly change the levels of p53 as shown before [38], but
induced an increase in p21 protein that was dependent on p53
(Figure 2G). Induction of p21 was markedly impaired by co-
transfecting cells with RPL11 siRNA (Figure 2G). Knockdown of
RPL11 using siRPL11-1 resulted in lower levels of p53, MDM2,
and in particular p21, also under normal conditions in U2OS cells
(Figure 2G, lane 6). Interestingly, depletion of RPS9 led to lower
levels of NP40-soluble RPL11 (Figure 2G, lane 2) but the fraction
of RPL11 bound to MDM2 remained the same and did not
decrease (Figure 2I). We wanted to know if the reduction in
RPL11 also could be seen in whole cell extracts and therefore
U2OS cells were transfected with siRPS9 or incubated in 5 nM
actinomycin D for 18 hours. This concentration of actinomycin D
selectively blocks RNA Pol I activity and prevents ribosome
biogenesis. We could confirm the results obtained when using the
milder lysis buffer also in whole cell extracts thus showing
decreased total levels of RPL11 (Figure 2H). Most of the studies in
the field have relied upon silencing RPL11 using one particular
siRNA so we found it of importance to compare RPL11 with
RPL5. We found that depletion of RPL5 could block p21
induction identical to RPL11 in RPS9 depleted cells (Figure 2J).
Silencing of RPL11 with morpholinos induces a p53-dependent
apoptotic response in zebrafish [42], and we therefore do not want
to rule out that RPL11 and RPL5 loss can to some extent induce
p53 activity or engage p53 related pathways in vivo. We also made
another observation from the experiment in figure 2G. First, the
knockdown of RPL11 caused a decline in RPL5 protein level to
the same extent as for RPL11 (Figure 2G, lane 6). This is
presumably because 28S rRNA is not efficiently processed in
RPL11 or RPL5 deficient cells [43] leading to a surplus of large
subunit r-proteins that are rapidly degraded [44]. It has recently
been shown by other groups that depletion of one individual r-
protein from one ribosome subunit results in down-regulation of
other proteins from the same subunit [45]. This finding might
have some implications as to why the regulation of MDM2 by
several ribosomal proteins seems to occur in a non-redundant
manner, but this cannot be the only explanation because then we
would find that knockdown of almost every r-protein can block
p53 stabilization which we do not see. In summary, we conclude
that RPL11 is required for the efficient induction of p53-
dependent responses in RPS9 depleted U2OS cells.
Is RPL11 Required for p53 mRNA Translation Following
Nucleolar Stress?
How does RPL11 control p53? Binding of RPL11 and RPL5
directly to MDM2 protein leads to stabilization of p53 via inhibition
of MDM2 E3 ubiqutin ligase activity [46]. However, other reports
also indicate critical roles for r-proteins in p53 mRNA translation
[33], [47]. Moreover, the significance of the interaction between
MDM2 and RPL11/RPL5 in terms of possible effects on p53
mRNA translation has remained somewhat unclear. This could be
relevant to investigate since MDM2 can boost p53 mRNA
translation as has been described to occur in some settings [48],
[49]. Indeed, it was suggested that interactions between RPL11/
RPL5 and MDM2 may serve a dual purpose to inhibit MDM2 E3
ligase activity, and to promote p53 mRNA translation at the same
time [48], [49]. On the other hand, MDM2 binds to RPL26 and
inhibits RPL26 mediated stimulation of p53 mRNA translation
[15]. Hence, we decided to re-visit p53 half-life and degradation and
to investigate p53 mRNA translation following nucleolar stress in
U2OS cells with and without RPL11. We first carried out a p53
protein half-life assay to confirm the increased stability of p53 after a
low dose actinomycin D exposure to induce nucleolar stress. Indeed,
a robust increase in the amount and stability of p53 protein was
seen, and essentially very little, if any, degradation of p53 occurred
in actinomycin D treated cells during the four hour chase
(Figure 3A). In contrast, the bulk of p53 protein in DMSO treated
control cells was degraded after less than one hour in cycloheximide
(Figure 3A). We then transfected U2OS cells with control or
siRPL11 for 24 hours and next treated all transfectants with 5 nM
actinomycin D overnight followed by a CHX chase. Loading was
adjusted to give a comparable starting amount of p53 to facilitate a
direct comparison. p53 was clearly more unstable in RPL11
depleted U2OS cells (Figure 3B). Residual stable p53 in siRPL11
samples at later time points probably stems from a population of
cells that have responded to actinomycin D but that have not been
transfected with siRPL11. We next reasoned that small molecules
that disrupt p53-MDM2 binding, block MDM2 transcription or
prevent p53 degradation by the proteasome thereby causing p53
accumulation by ‘‘default’’ would act independently of any
ribosomal protein-MDM2 interaction. We therefore treated U2OS
cells with Nutlin-3. The Nutlin-3 compound disrupts the p53-
MDM2 interaction but does not prevent the binding of MDM2 to
p53 mRNA [48], [49]. We transfected cells with two different RPL5
siRNA oligos overnight followed by treatment of cells with 5 nM
actinomycin D or 10 mM Nutlin-3 for an additional 18 hours
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PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9578Figure 2. Silencing of RPS9 induces a limited senescence response in U2OS cells. (A) Phase contrast images reveals morphology of human
U2OS osteosarcoma cells transfected with siRNA targeting RPS9 or p53. (B–C) Increased expression of DNA damage and replication stress markers in
U2OS cells depleted of RPS9 and analyzed 72 hours after siRNA transfection. U2OS cells were fixed and stained with an antibody towards c-H2AX and
a phospho-ATM/ATR substrate antibody. (D) Quantification of SA-b-gal positive U2OS cells in cultures depleted of RPS9. Shown is one representative
experiment out of two. (E) Cells were transfected with siCtrl, RPS9, RPL11, p53, or p21 siRNA as indicated. The cells were incubated with BrdU at
24 hour post transfection for another 24 hours and the cells were then fixed and stained with anti-BrdU antibodies and the average of the BrdU-
positive cells is shown (%). (F) Co-depletion of RPL11, p53 or p21 partially impaired RPS9 knockdown-mediated inhibition of cell proliferation. U2OS
cells were transfected with siCtrl, siRPS9, sip53, sip21 or siRPL11 in combinations as indicated. Final concentration of siRNA was 100 nM in each case
and compensation was made with siCtrl. Cells were counted 72 hours post-transfection and shown is mean and SEM from three different
experiments performed in triplicate at independent occasions and normalized to siCtrl set to 100%. (G) Co-knockdown of RPL11 attenuated induction
of p21 and MDM2 proteins caused by knockdown of RPS9. U2OS cells were transfected with combinations of siRNA as indicated. Cell lysates were
subjected to immunoblotting and the expression of p53, MDM2, p21, RPL11, RPL5 and RPS9 was determined as indicated. The protein lysate from
each sample was split for three different blots and each probed with actin as a loading control. (H) U2OS cells were transfected with siRPS9-1 or
siRPL11-2 for 48 hours or treated with 5 nM actinomycin D for 18 hours after which the cells were harvested directly into 2% SDS containing lysis
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p53 accumulation following 5 nM actinomycin D, and in particular
the induction of p21 was decreased (Figure 3C, lane 3 and 4). In
contrast, the effect on p53 and p21 protein levels when we depleted
RPL5 in the presence of Nutlin-3 was marginal when normalized to
actin. Therefore RPL5 was not required for stabilization of p53, as
well as induction of MDM2 and p21 proteins, in Nutlin-3 treated
cells. We next wanted to see if other small subunit r-proteins
including RPS9 are required for p53 stabilization after actinomycin
D treatment. We depleted cells of RPS6, RPS9, RPS17 and RPS24
but silencing of these proteins did not block p53 protein stabilization
caused by actinomycin D (Figure 3D). This shows that RPL11 but
n o tR P S 9p l a y sac r i t i c a lr o l ei nt h ep 5 3r e s p o n s ef o l l o w i n g
actinomycin D treatment.
Finally, we wanted to investigate the synthesis of new p53 protein
under conditions of actinomycin D exposure or after silencing of
RPS9, in the presence or absence of siRPL11. We labeled U2OS
cells for 15 minutes and used p53 immunoprecipitation to monitor
total and newly synthesized p53 but found no indication that RPL11
is required for p53 protein synthesis in this experimental setting
(Figure 3E and F). A marginal increase in new p53 protein could be
seen in actinomycin D treated cells (Figure 3E), but the
Figure 3. Analysis of p53 mRNA translation in RPL11 depleted cells. (A) U2OS cells were treated with 5 nM actinomycin D for 18 hours or
DMSO only followed by a cycloheximide chase (CHX) to estimate p53 protein degradation rates. Cell lysates from each time point were subjected to
immunoblotting and the expression of p53 determined in relation to actin levels. (B) U2OS cells were transfected with siCtrl or siRPL11 overnight
followed by treatment with actinomycin D for an additional 18 hours. This was followed by CHX chase as above for indicated time. In this case the
loading was adjusted to give comparable starting amounts of p53 facilitating analysis of degradation that is more rapid in RPL11 transfected cells. (C)
U2OS cells were transfected with siRNAs targeting RPL5 or with siCtrl. Cells were thereafter treated with Nutlin-3 (10 mM) or actinomycin D (5 nM) for
18 hours. The blotting membrane was probed for RPL5, MDM2, p53 and p21. (D) Depletion of ribosomal proteins RPS6, RPS9, RPS17 and RPS24 does
not prevent p53 accumulation and p21 induction following actinomycin D treatment but depletion of RPL11 did. U2OS cells were transfected with
indicated siRNA for 18 hours followed by treatment with actinomycin D (5 nM) for another 18 hours and expression levels of p53 and p21 were
measured by immunoblotting. (E) p53 synthesis in actinomycin D treated cells with or without siRPL11. Total p53 and RPL11 is shown by
immunoblotting and newly synthesized p53 was immunoprecipitated with DO1 antibody and visualized by autoradiography. The experiment was
carried out 36 hours after siRNA transfection. (F) Evaluation of p53 mRNA translation in U2OS cells depleted of RPL11, RPS9, RPS9+RPL11, or in cells
treated with actinomycin D (5 nM) in the presence or absence of RPL11 siRNA. Shown is the amount of newly synthesized p53 during 15 minutes
relative to the total amount of p53, and compared to overall protein level as detected with Ponceau S. The experiment was carried out 36 hours after
siRNA transfection.
doi:10.1371/journal.pone.0009578.g003
buffer. Cell lysates were subjected to immunoblotting using antibodies towards RPL11 or RPS9 (w.c.e= whole cell extract). (I) Co-
immunoprecipitation of MDM2 and RPL11 in U2OS cells transfected with siRNA targeting RPS9. MDM2 was immunoprecipitated with N20 antibody
followed by detection with SMP14 monoclonal or a monoclonal towards RPL11. Note, that different exposure times were used for RPL11 IP and input
blots. (J) U2OS cells were transfected with siRPS9-1 alone or in combination with siRPL5-2 for 72 hours, after which cells were harvested and the level
of p21 as a read-out for p53 activity was analyzed by immunoblotting.
doi:10.1371/journal.pone.0009578.g002
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stabilize the pool of newly synthesized p53, and the overall levels of
translation was slightly higher in this sample. The results taken all
together support the notion that RPL11 predominantly controls p53
at a post-translational level and that RPL11 is not strictly required
for p53 synthesis in this particular experimental setting, but an
additional minor effect on p53 production is not ruled out.
RPS9 Silencing Impairs Production of 18S rRNA and
Induces p53 in Glioma Cells
So far, most studies on ribosomal protein-p53 signaling have
been carried out in U2OS cells and it remains unclear if, or to
what extent, this regulatory mechanism operates in other cell types.
We found that endogenous RPS9 could be efficiently silenced in
U343MG and in U87MG glioma cells whereas no change in RPS9
expression was seen in U1242MG cells upon siRPS9 transfection
(Figure 4A). Of note, is the already low level of RPS9 in untreated
U1242MG cells. A clear reduction in the number of cells in
cultures treated with siRPS9 relative to siCtrl treated cultures was
seen for U87MG, U343MG, and U343MGa Cl2:6 cells but not
for U1242MG (Figure 4B). As a further specificity control, we
verified that the RPS9 siRNA oligonucleotide had no effect on
mouse NIH3T3 cell proliferation whereas a mouse rps9 siRNA
oligo efficiently inhibited the proliferation of these cells (Figure
S1C). To assess the effect of RPS9 knockdown on the synthesis of
mature 28S and 18S rRNA we labeled knockdown and control
U343MGa Cl2:6 cells with [
3H]-uridine for 2 hours and examined
the labeled and isolated rRNA following gel electrophoresis and
blotting to a nylon membrane. We found that in RPS9 knockdown
cultures very little mature 18S rRNA was produced during the
labeling period (Figure 4C), however overall cellular RNA
synthesis continued (Figure 4D). Actinomycin D (5 nM) efficiently
blocked synthesis and labeling of rRNA (Figure 4C and D). In an
experiment using [
3H]-L-methyl methionine to label newly
synthesized rRNA we found that the production of 18S rRNA
was clearly impaired (Figure 4E). There was a marginal decrease in
the new synthesis of 28S rRNA. Moreover, the depletion of RPS9
in U343MGa Cl2:6 cells decreased the overall incorporation of
[
35S]-methionine into nascent protein by 30–50% (Figure 4F). The
mechanism of maintaining rRNA synthesis at high levels despite
activation of p53 remains to be determined. As suggested by
others, this might be a general compensatory mechanism in
response to a deficiency in ribosomes [50].
We observed that nucleoli in RPS9 depleted U343MGa Cl2:6
cells, similar to U2OS cells, were more contrasted and phase-dense
than in siCtrl treated cells (Figure S2B), and data not shown. We
double stained cells that had been depleted of RPS9, for p53 and
the nucleolar marker fibrillarin. An increase in p53 levels was seen
in the majority of RPS9 siRNA treated U343MGa Cl2:6 cells
(Figure 5A). To quantify induction of p53 in glioma cells we
transfected U343MGa Cl2:6 cells (wt p53) with siRNA targeting
RPS9 and other ribosomal proteins (Figure 5B). We found that
RPS6, RPS17 and RPS24 silencing induced levels of p53, similar
to that seen in response to depletion of RPS9 whereas no increase
in p53 protein levels was seen after depleting RPL11 or RPL5.
Finally, depletion of RPS9 in U343MGa Cl2:6 cells induced p53-
dependent cell cycle arrest according to a BrdU incorporation
assay, similar to U2OS cells (Figure 5C).
RPS9 Silencing Promotes Morphological Differentiation
of Glioma Cells
Visual inspection of U343MGa Cl2:6 cells under the phase
contrast microscope revealed that cells depleted of RPS9 exhibited
a strikingly different morphology resembling differentiation. At
48 hours, cells started to undergo a distinct morphological change
characterized by the occasional formation of long and rather thin
cytoplasmic processes and of round cellular bodies (Figure 6A).
Using an established marker for astrocyte differentiation, glial
fibrillary acidic protein (GFAP), we detected an intensified
expression of GFAP in cells with spiking protrusions after
depletion of RPS9 (Figure 6B). We found no evidence of cell
death in U343MGa Cl2:6 cell cultures depleted of RPS9 such as
an increase in the number of floating cells, or attached cells with
DNA condensation. Also, senescence or appearance of DNA
damage response marker protein foci following depletion of RPS9
was not observed in U343MGa Cl2:6 glioma cells (data not
shown). To evaluate the impact on p53 pathway activation in
U343MGa Cl2:6 cells in this setting, we depleted RPS9 alone or
together with either RPL11, p53, or p21. Evidently, knockdown of
RPL11, p53 or p21 partially rescued the cell proliferation defect,
as measured at 72 hours of RPS9 depletion, but failed to restore
cell counts to the level seen in siCtrl treated cultures (Figure 5D).
SiRPS9 treated cultures had grown 54% (611.6) whereas
siRPS9+sip53 cultures had a cell count of 87% (67.2) compared
to siCtrl. Also, RPL11 depletion (only) in the long-term negatively
affected cell proliferation (68%65.0, at 72 hrs). When we co-
depleted cells of RPS9 together with RPL11, p53 or p21, the
morphological changes of U343MGa Cl2:6 cells were reversed
(Figure S4). Similar to U2OS cells, it was found that induction of
p21 was markedly impaired when co-transfecting siRNA against
RPL11 (Figure 5E). Screening of other r-proteins including RPS6,
RPS19, RPS17 and RPS24 revealed a knockdown phenotype
similar to that of siRPS9 treated cells provided the p53 pathway
was activated, suggesting that the response of U343MGa Cl2:6
cells is not unique to RPS9 loss (Figure S5).
Induction of Cell Death in Cervical Carcinoma HeLa Cells
Depleted of RPS9
In contrast to U343MGa Cl2:6 cells and other glioma cell lines
tested, that did not undergo apoptosis, a significant number of
HeLa cervical carcinoma cells showed signs of membrane
blebbing, and then detached from the dish 36–48 hours after
RPS9 silencing (Figure 7A). By trypan blue exclusion assay these
cells were scored as not viable. DAPI staining of remaining
attached cells showed frequent DNA condensation and many cells
lacking cytoplasmic punctuate cytochrome C (Figure 7B and C).
Silencing of other r-proteins including RPS6, RPS19, RPS17,
RPS24 and RPL26 revealed a similar cellular phenotype
suggesting that the apoptotic response of HeLa cells is a common
response to ribosomal protein loss in this cell line (Figure 7H). To
determine whether p53 pathway is activated we depleted RPS9
alone or together with either RPL11, p53, or p21. Interestingly,
depletion of RPL11, p53 or p21 with siRNA could each one
individually partially restore viable cell counts 72 hours post-
transfection (Figure 7A and D). siRPS9 treated cells had only
grown 30% (64.3), whereas siRPS9/sip53 treated cell cultures
had a cell count that was 66% (64.9) of the control. Similar to
U2OS and Cl2:6 cells there was no major change in p53 protein
level in cells treated with RPS9 siRNA (Figure 7E), but we found
that p21 protein was reduced in RPS9 knockdown HeLa cells,
presumably as a consequence of the predominant apoptotic
response. How p53 chooses to induce either apoptosis or cell cycle
arrest is debated but it has been shown that in cells that are
committed to p53-dependent apoptosis there is an MDM2
controlled mechanism triggering p21 degradation [51]. We next
evaluated the role of p53 in siRPS9 induced HeLa cell cycle arrest
and apoptosis separately. Analysis of apoptotic cells using
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revealed a 7% reduction in the number of dying HeLa cells when
siRPS9-1 was co-transfected with sip53 (Figure 7F). In addition,
twice as many HeLa cells incorporated BrdU following co-
depletion of RPS9 and p53 compared to siRPS9 transfected cells
only (Figure 7G). Depletion of RPL11 or RPL5 also led to
Figure 4. Ribosomal protein S9 is required for 18S rRNA production. (A) RPS9 knockdown efficiency in glioma cell lines U87MG, U343MG
and U1242MG as determined by immunoblotting for RPS9 relative to actin. (B) Cell lines from the experiment performed in (A), and U343MGa Cl2:6
cells, were transfected with siCtrl or siRPS9-1 and after 72 hours the number of viable cells relative to siCtrl treated cells set to 100% was determined
for each cell line. For this assay, equal numbers of cells were plated in triplicate at day 0, and cultures transfected on day 1, and then trypsinized and
counted 72 hours later. (C) Total RNA from the experiment in (C) was separated on a 1% agarose-formaldehyde gel, transferred onto nylon
membranes and subjected to autoradiography. Newly synthesized 18S rRNA is indicated, while the total level of 18S rRNA transferred to the
membrane was visualized by methylene blue staining. Actinomycin D at a final concentration of 5 nM was added 3 hours prior to labeling and served
as a control for inhibition of rRNA transcription. (D) U343MGa Cl2:6 cells were transfected with siRNAs as indicated and after 72 hours the cells were
labeled with [
3H]-uridine for another 2 hours. Radioactive incorporation was measured using liquid scintillation counting and expressed as cpm/mg
total RNA and then normalized to the level in siCtrl transfected cells set to 100%. Results presented are averages and SEM representing three different
experiments. (E) U343MGa Cl2:6 cells transfected with siRPS9-1 or siCtrl for 72 hours were incubated with [methyl-
3H]-L-methionine for 2 hours to
label the newly synthesized rRNA precursors followed by isolation of total RNA. Equal amounts of total RNA were next separated on a 1% agarose-
formaldehyde gel, transferred onto nylon membranes, and subjected to autoradiography. Newly synthesized 18S rRNA is indicated (left panel) and
total 28S and 18S rRNA transferred to the membrane was visualized by methylene blue staining (right panel). An asterix denotes apparent
accumulation of an intermediate rRNA precursor. (F) U343MGa Cl2:6 cells transfected with siRNAs for 72 hours as indicated were labeled with [
35S]-
methionine. Cells were starved of methionine and cysteine for 30 min prior to the addition of [
35S]-methionine. After labeling for 2 hours the protein
extracts were prepared. Radioactive incorporation was measured by using liquid scintillation counting and expressed as cpm/mg total protein and
then normalized to control cells set to 100%. Results presented are averages and SEM representing three different experiments. Cycloheximide
(100 mg/ml) was used as a positive control to inhibit protein synthesis.
doi:10.1371/journal.pone.0009578.g004
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independent effect (Figure S1E). In summary, both cell cycle
arrest and apoptosis in HeLa cells have a clear p53-dependent
component in the case of RPS9.
Discussion
Outcomes of ribosomal protein loss in cultured mammalian cells
and in cells in vivo have to date not been investigated in any greater
detail but such studies have been facilitated by different
conditional gene knock-out and RNA interference strategies.
The drawback with RNAi methodology is the difficulty to achieve
a strict 100% knockdown. Also in this setting we now know that a
pre-existing pool of the ribosomal protein is present in the form of
functional cytoplasmic ribosomes. These ribosomes support
growth and survival of the cells, while activation of cellular
checkpoints prevents further cell division if ribosome biogenesis is
defective [52].
Using a set of cancer cell lines we investigated the proliferation
and phenotypic response to RPS9 depletion. Silencing of RPS9
reduced the formation of new 18S rRNA. This also resulted in
decreased DNA synthesis and a decline in global protein synthesis.
Reduction in cell proliferation rate was due to p53 activation
similar to that observed after depletion of RPS6 [30]. But silencing
of RPS9 and RPL11 also resulted in p53-independent inhibition of
cell proliferation in the longer run. Perhaps, an expected outcome
Figure 5. Depletion of ribosomal proteins activates p53 in glioma cells. (A) Increased nuclear expression of p53 is seen in the majority of
U343MGa Cl2:6 cells after silencing of RPS9. Cells were stained for p53 and nucleolus marker fibrillarin (p53-green, fibrillarin-red, DNA-blue). (B)
U343MGa Cl2:6 cells were transiently transfected with siRNAs targeting RPS9 and other ribosomal proteins, 100 nM final concentration in each case,
as indicated in the figure. Cells were harvested 48 hours after transfection and levels of p53 protein determined by immunoblotting. (C) U343MGa
Cl2:6 cells were transfected with siCtrl, RPS9-1, RPS9-2 or p53 siRNA as indicated. The cells were incubated with BrdU at 24 hours post transfection for
another 24 hours. The cells were fixed and stained with anti-BrdU antibodies and the average of BrdU-positive cells is shown (%). (D) Knockdown of
RPL11, p53 or p21 partially restores cell counts caused by the knockdown of RPS9. U343MGa Cl2:6 cells were transfected with siCtrl or with RPS9
siRNA in combination with or without RPL11, p53 or p21 siRNA and cells were counted 72 hours after transfection. Shown is the mean and SEM of
three independent experiments normalized to control. (E) Co-depletion of RPL11 with siRPS9 in U343MGa Cl2:6 cells impaired the induction of p21
caused by silencing RPS9. Cells were transfected with siRNAs in combinations, or alone, as indicated in the figure and cell lysates were subjected to
immunoblotting to detect the expression of actin, p53, MDM2, RPL11, RPS9 and p21.
doi:10.1371/journal.pone.0009578.g005
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ruled out that additional p53-independent checkpoints are
activated. What was intriguing to us was the variety and strength
of cellular responses observed following depletion of RPS9. We
found that silencing of RPS9 promoted p53- and p21-dependent
differentiation of U343MGa Cl2:6 glioma cells as evidenced by
intensified expression of GFAP and profound changes in cell
morphology. Interestingly, a very similar phenotype was seen
during treatment of these cells with a histone deacetylase inhibitor
trichostatin A [53]. In another study, it was found that p16INK4a
expression promoted an increase in the expression of GFAP that
was coupled to a stellate cell phenotype in parental U343MGa
cells [54]. There are also other instances where lower expression of
a ribosomal protein triggers differentiation-like responses. For
example, decreased levels of RPL29 induced differentiation of
LS174T colon cancer cells with increased expression of two known
markers of differentiation, galectin-4 and mucin-2 [55].
Osteosarcoma cells U2OS accumulated higher levels of p21,
similar to U343MGa Cl2:6 cells, but did in contrast develop a
more pronounced senescence-like morphology. In fact, a fraction
of the cells stained positive for SA-b-gal and DNA damage/
replication stress markers. Although it has been found that loss of
ribosomal protein S6 activates p53 in the absence of a detectable
DNA damage response in vivo [7], [11], one report described an
increase in p53 Ser-15 phosphorylation following depletion of
WDR12, a protein involved in ribosome biogenesis [56]. It is
conceivable that activation of p53 and induction of p21 in the
U2OS cell line caused by RPS9 silencing may result in stalled
replication forks resembling a situation of DNA replication stress.
HeLa cells showed decreased proliferation and apoptosis
following depletion of ribosomal proteins. The knockdown of
RPS19 also induces HeLa cell apoptosis similar to RPS9 [57]. In
another study, it was demonstrated that RPS19 deficiency causes
apoptosis and accelerated loss of erythroid progenitors while not
affecting terminal differentiation [58]. p53 is under complete
control of E6/E6AP complex rather than controlled by MDM2 in
HeLa cells [59]. We would then assume that the RPL11-MDM2-
p53 pathway is inactive or dormant in this cell line, but as a matter
of fact, a low dose actinomycin D can reactivate p53 in HeLa cells
[60]. Similarly, we found that reduced levels of RPS9 activated the
p53 pathway. Induction of all p53-dependent phenotypes,
senescence, differentiation and apoptosis that occurred in the
respective cell cultures could be attenuated by co-depletion of
RPL11.
How then is p53 activity controlled by RPL11 following RPS9
silencing? Any discussion regarding this has to start with MDM2.
Regulation of MDM2 activity is complex given the abundance of
many ribosomal and nucleolar proteins that can bind to MDM2,
for example; p14ARF/p19ARF [61], nucleostemin[62], B23/
NPM [63] and C23/nucleolin [64]. Several of these proteins could
in different combinations modulate MDM2 functions after stress.
One example is ribosomal protein L23 that is released from the
nucleolus after actinomycin D treatment and that directly binds
and inhibits MDM2 thereby activating p53 [6],[24]. Paradoxical-
ly, knockdown of RPL23 itself leads to p53 activation, but at the
same time it attenuates p53 induction by actinomycin D that on its
own triggers accumulation of much higher levels of p53 protein
than RPL23 loss [6],[24]. It had remained a possibility that
depletion of RPL11 would specifically affect the translation of p53
mRNA leading to lower levels of p53 in a process that could
depend on MDM2, or that silencing of RPL11 could lead to a
global translation inhibition and thus also include p53 mRNA. To
this end, we carried out analysis of p53 mRNA translation in cells
exposed to actinomycin D, but RPL11 was not strictly required for
p53 protein synthesis in this setting, although a minor effect is not
ruled out.
We did not detect increased steady state levels of RPL11 in total
or in NP40 soluble cellular protein extracts in RPS9 depleted cells,
yet the p53 pathway was activated as evidenced by p53-dependent
induction of p21. Moreover, actinomycin D led to lower levels of
RPL11. Why are levels of RPL11 decreasing? One explanation is
that knockdown of RPS9 causes a decline also in large subunit
proteins, likely as a general cellular response to a reduced cell
proliferation rate. A marginal reduction in some large subunit r-
proteins as an ‘‘adaptive’’ response has previously been seen in
other cell lines in response to RPS19 knock-down besides the more
dramatic effects on r-protein levels from the same subunit [45].
Actinomycin D blocks the new synthesis of rRNA and production
of ribosomes and subsequently this also leads to lower levels of
RPL11. We could reproducibly see reduced levels of p53, MDM2
and in particular p21 proteins in RPL11 siRNA transfected U2OS
cells also under normal conditions suggesting that RPL11 may act
as a constitutive regulator of MDM2, at least in some cell types.
We also found that the pool of RPL11 bound to MDM2 remained
fairly constant despite decreased levels of RPL11, apparently
sufficient to allow control of MDM2 and p53. Hence, a small
fraction of RPL11 bound to MDM2 may set the threshold for the
p53 response should stress occur. Only a complete block in new
Figure 6. Silencing of RPS9 drives differentiation of glioma
cells. (A) Phase contrast microscopy shows the morphology of
U343MGa Cl2:6 cells 72 hours after transfection with siCtrl or siRPS9-
1. Cells depleted of RPS9 protein show a subset of broadly bipolar cells,
some of which form long cytoplasmic processes and spiking
protrusions. (B) Depletion of RPS9 leads to morphological changes
and accumulation of GFAP protein as evidenced by immunofluores-
cence staining for GFAP protein (GFAP-red, DNA-blue). These changes
were reversed by co-transfecting sip53.
doi:10.1371/journal.pone.0009578.g006
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depleted of RPS9. RPS9 siRNA treated cells show cell death, and few cells overall, as indicated by an increase in floating cells and a clear reduction in
number of adherent cells. This effect was partially rescued by co-depletion of p53, p21 or RPL11. (B) Staining of HeLa cell nuclei using DAPI reveals the
typical DNA condensation that usually occurs during apoptosis in cells depleted of RPS9 as indicated by asterix in the figure. (C) Cytochrome C is not
detected in mitochondria in a fraction of HeLa cells depleted of RPS9 as indicated with an asterix (Cyt C-red, DNA-blue). No DNA condensation or
cytochrome C release is seen in siCtrl treated cells. (D) Knockdown of RPL11, p21 or p53 partially restores the lower cell counts caused by the
knockdown of RPS9. HeLa cells were transfected with siRPS9 alone or in combination with sip53, sip21 or siRPL11 as indicated in the figure. Cells were
harvested and counted 72 hours post-transfection. Shown is mean and SEM of three independent experiments. (E) HeLa cells were transfected with
indicated siRNAs for 72 hrs and expression levels of p53, p21, RPS9, RPL11 and RPL5 were analyzed by immunoblotting. A long exposure time was
used for endogenous p53 detection. (F) HeLa cells were transfected with siCtrl, siRPS9, or sip53 as indicated and the number of cleaved PARP-1
product positive cells determined by immunostaining. Shown is one independent experiment in triplicate. (G) Cells were transfected with siCtrl,
siRPS9, or sip53 as indicated. The cells were incubated with BrdU at 24 hours post transfection for another 24 hours and were then fixed and stained
with anti-BrdU antibodies and the average of the BrdU-positive cells is shown (%). (H) HeLa cells were transfected with siRNA targeting different r-
proteins as indicated in the figure.
doi:10.1371/journal.pone.0009578.g007
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case when siRNA is used. Rapid nucleolar release of RPL11
occurring in response to actinomycin D [65], transcriptional
induction of RPL11 by c-Myc [66], or translational induction of
RPL11 [30] will further increase the pool of RPL11 protein that
could be captured by MDM2. We presumably also have to keep in
mind that the bulk of free ribosomal proteins are unstable and
rapidly degraded also in the nucleus [39], [40], and that the
amount of ribosomal protein bound to MDM2 represents just a
minor fraction of the total cellular pool as indicated by
fractionation experiments [24]. Interestingly, it has been shown
that MDM2 promotes the stability of RPL11 by facilitating Nedd8
modification of RPL11 [67]. Reducing the levels of MDM2 leads
to a decreased expression of RPL11 [67], something that we have
observed as well. Therefore, it appears that MDM2 and a small
fraction of RPL11 when bound together in a complex are both
being protected from degradation, although the exact mechanism
remains unclear.
While the presence of RPL11 in cells is required for
maintaining the cellular levels of MDM2 and p53 in response
to ribosomal/nucleolar stress, we cannot strictly rule out on basis
of our data presented here, that other stress sensing molecules act
upstream or in parallel with RPL11 to initiate p53 and p21-
dependent responses, such as differentiation, following loss of
RPS9. Moreover, p53 related or p53-independent mechanisms
could also become activated. Regardless of the possible existence
of other mediators of ribosome dysfunction it is striking that
depletion of several r-proteins mutated in DBA (RPL11, RPL5
and RPS7) does not seem to engage the p53 pathway in different
mammalian normal and cancer cell lines. However, it remains
unclear to what extent the lack of p53-dependence is relevant in
the pathogenesis of Diamond-Blackfan anemia since these
patients frequently display mutations in RPL11 and RPL5 [17],
and as we show here, RPL11 knockdown resulted in a significant
inhibition of cell growth as well. From another angle, it is possible
that inhibiting the expression or function of some ribosomal
proteins, such as RPS9, would be one way to reinitiate
differentiation processes and stop the growth of rapidly
proliferating malignant tumor cells. However care must be taken,
as some r-proteins are essential in regulation and induction of the
cellular p53 response itself.
Materials and Methods
Cell Culture
Glioma cells U343MG, U1242MG, and U87MG have been
previously well characterized [68], [69]. Two cell lines (U343MG
and U343MGa) with different phenotypic characteristics were
initially established from the same human glioblastoma multiforme
biopsy. Low passage cultures of the U343MGa line have a
pleomorphic appearance, whereas high passage cultures are more
homogeneous, with small polygonal or short fusiform cells. This
cell line, irrespective of passage level, is 100% GFAP positive. Data
on clonal derivatives of the line U343MGa (Cl2:6) have been
published [70]. These clones are morphologically homogeneous
and retain the GFAP positive phenotype. The U343MGa Cl2:6
cell line (wt p53) was primarily selected for investigation of the
effects resulting from loss of RPS9. Cervical carcinoma cells
(HeLa) and osteosarcoma cells (U2OS) were purchased originally
from ATCC and were mycoplasma-free. Cells were cultured in
Iscoves Modified Dulbecco’s medium (IMDM) containing 10%
fetal bovine serum, antibiotics (100 mg of penicillin and 50 mgo f
streptomycin sulfate/mL), and 2 mM glutamine at 37uC, 5%
CO2.
Chemicals
Transcription inhibitor actinomycin D was prepared as a 1 mg/
ml stock solution in DMSO and used at a final concentration of
5 nM. Nutlin-3 was prepared as a 10 mM stock in DMSO
and used at a concentration of 10 mM. Cycloheximide was
prepared in ethanol (100 mg/ml). All drugs were purchased from
Sigma-Aldrich.
RNA Interference
Oligofectamine was used to transfect cells in 6-well plates with
siRNA, according to the manufacturer’s instructions (Invitrogen).
Cells were usually harvested after 72 hours unless otherwise
stated. A list of siRNA oligonucleotides for human ribosomal
proteins that was used is given in Table 1, and based mostly on
the literature of already published and validated sequences. For
human p53 siRNA the sequence was sense 59GUAAUCUA-
CUGGGACGGAAdTdT39 and antisense 59UUCCGUCCCA-
GUAGAUUACdCdA39, and for human p21/CDKN1A sense
59AGAUUUCUACCACUCCAAAdTdT39 and antisense:
59UUUGGAGUGGUAGAAAUCUdGdT39. The siRNAs were
purchased from Applied Biosystems and knockdown efficiencies
were verified by immunoblotting.
Labeling of Newly Synthesized RNA and Protein
To analyze newly synthesized rRNA, cells growing in a 6-well
plate were labeled in regular medium with a final concentration of
3 mCi/ml [5,6-
3H]uridine (Perkin Elmer) per well, for two hours.
Table 1. Sequences of ribosomal protein siRNA
oligonucleotides used in this study.
Ribosomal protein siRNA sequence
RPS6 Sense 59GAAAGCCCUUAAAUAAAGAdTdT 39
Antisense 59UCUUUAUUUAAGGGCUUUCdTdT 39
RPS9-1 Sense: 59GGAUUUCUUAGAGAGACGCdTdT 39
Antisense: 59GCGUCUCUCUAAGAAAUCCdTdC 39
RPS9-2 Sense: 59GGAAGAAUGCCAAGAAGGGdTdT 39
Antisense: 59CCCUUCUUGGCAUUCUUCCdTdC 39
rps9-1 (mouse) Sense: 59 CAUCCUUCAUUGUUCGCCUdTdT 39
Antisense: 59AGGCGAACAAUGAAGGAUGdGdG 39
RPS17 Sense 59GCGAAUUCAGAGAGGCCCAdTdT39
Antisense 59UGGGCCUCUCUGAAUUCGCdTdT39
RPS19 Sense: 59UGGCGGCCGCAAACUGUCAdTdT 39
Antisense: 59UGACAGUUUGCGGCCGCCAUC 39
RPS24 Sense 59GUGCCUAAGACAGAAAUUCdTdT39
Antisense 59GAAUUUCUGUCUUAGGCACdTdG39
RPL5-1 Sense: 59GAGAGAAUCCAGUCUAUGAdTdT39
Antisense: 59UCAUAGACUGGAUUCUCUCdGdT39
RPL5-2 Sense: 59CAGUUCUCUCAAUACAUAAdTdT39
Antisense: 59UUAUGUAUUGAGAGAACUGdTdT39
RPL11-1 Sense: 59 GGUGCGGGAGUAUGAGUUAdTdT 39
Antisense: 59UAACUCAUACUCCCGCACCdTdT 39
RPL11-2 Sense: 59GCAUUGGUAUCUACGGCCUdTdT39
Antisense: 59AGGCCGUAGAUACCAAUGCdTdT39
RPL26 Sense: 59GGUUGUACGUGGACACUAUdTdT39
Antisense: 59AUAGUGUCCACGUACAACCdTdG39
doi:10.1371/journal.pone.0009578.t001
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using L-[methyl-
3H] methionine (Perkin Elmer) to a final
concentration of 50mCi/ml also that for two hours. Total RNA
was isolated using Trizol reagent (Invitrogen). Incorporation of
radioactivity was measured using liquid scintillation counting and
isolated RNA was loaded onto 1% agarose-formaldehyde gels.
RNA was also blotted onto Hybond N+ membranes (Amersham)
and sprayed with En
3Hance spray (Perkin-Elmer), and subjected
to fluorography for 1–3 days using Biomax MS-1 film and a
Biomax transcreen LE (Perkin Elmer). To measure protein
synthesis, cells were starved in methionine/cysteine free DMEM
medium (Invitrogen) supplemented with dialyzed FCS (Gibco,
Invitrogen) for 30 minutes, followed by a three hour pulse with
50 mCi/ml [
35S]-methionine (Perkin Elmer). Protein extracts were
prepared and total radioactive isotope incorporation was mea-
sured using liquid scintillation counting and normalized to cpm/
mg total protein.
Cell Proliferation and Cell Death Analysis
To measure proliferation, cells were seeded in 6-well plates and
transfected with siRNA on the following day at around 30%
confluence. Cells were then trypsinized and counted in triplicate at
time points indicated, usually 72 hours after transfection. The
BrdU incorporation assay was performed as in reference [62] and
senescence associated b-gal assay was essentially carried out as
described [71]. Cell viability was determined with trypan blue.
Apoptotic cells were scored by DAPI to reveal nuclear DNA
condensation complemented with analysis of PARP1 cleaved
product in adherent cells using immunofluorescence with an
antibody specific for cleaved PARP1 product (Cell Signaling
Technology).
Western Blotting
Cells were scraped into 0.5% NP-40 lysis buffer consisting of
0.5% Nonidet P-40, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
50 mM NaF, 1 mM NaVO3, 1 mM dithiothreitol, 16 protease
inhibitor cocktail (Roche). Cells were extracted for 10 minutes on
ice and the lysates cleared by centrifugation. Alternatively, as
indicated in the figures, an equal number of cells was collected
directly into 2% SDS containing sample buffer resulting in whole
cell extracts. Samples were loaded on a 10 or 12% Bis-Tris gel
(Invitrogen) and blotted onto PVDF membranes. Membranes
were incubated in 5% milk blocking solution with primary
antibodies overnight, followed by three washes in PBS, and then
incubated with secondary HRP conjugated antibody at room
temperature for an additional two hours. After three washes in
PBS, proteins were visualized with ECL reagent (Amersham
Biosciences) or West Pico. For p53 and p21 in HeLa cells we used
West Femto detection reagent (Pierce). Antibodies used in this
study are listed in Table S1.
Analysis of Newly Synthesized p53
p53 protein translation was measured in U2OS cells that were
labeled with 0.4 mCi L-[
35S]methionine and L-[
35S]cysteine
(Easy Tag EXPRESS, Perkin–Elmer) for 15 minutes, followed by
immediate cell lysis in ice-cold 0.5% NP40 lysis buffer. Cell
lysates containing equal amounts of proteins were immunopre-
cipitated with monoclonal anti-p53 antibody DO-1 (Sigma
Aldrich) or IgG control overnight at 4uC, followed by one hour
incubation with Protein A/G mixture beads (Amersham). After
three washes of the beads in lysis buffer the immunoprecipitated
material was resolved by 12% SDS-PAGE and visualized by
autoradiography.
Immunofluorescence
Cells grown and treated on coverslips in 6-well plates were
washed two times in PBS, fixed using 4% PFA for 15 minutes,
washed two times in PBS, permeabilized with 0.2% Triton X-100
for three minutes, washed three times in PBS, and then blocked for
30 minutes in blocking buffer (0.5% BSA in 1x PBS). Primary and
secondary antibodies were diluted in blocking buffer. The primary
antibodies were incubated with the cells for 60 min at room
temperature followed by three washes in PBS. The secondary
fluorochrome-conjugated antibodies were diluted in blocking
buffer and incubated with the cells for an additional 45 min.
After three PBS washes, the slides were mounted with Vectashield
anti-fading agent (Vector) containing DAPI. Glass slides were
analysed using a (3D) Zeiss Axioplan II microscope controlled by
Axiovision 3.1 software and equipped with Plan-Apochromat
636/1.4 and Plan-Neofluar 1006/1.30 objectives.
Supporting Information
Figure S1 Silencing of endogenous RPS9 in U2OS. A) The use
of an anti-RPS9 antibody shows a primary localization of RPS9 in
nucleoli and the cytoplasm of paraformaldehyde fixed U2OS cells.
The nucleolar signal is lost in most cells after silencing of RPS9. B)
Efficiency of RPS9 silencing by RPS9-1 siRNA. U2OS cells were
transfected to give indicated final concentrations of the siRNA and
cell extracts were prepared in NP40 lysis buffer. Protein lysates
were separated using SDS-PAGE and immunblotting shows the
levels of RPS9, C23/nucleolin and actin. C) Silencing of mouse
Rps9 using a mouse specific siRNA in NIH3T3 cells results in
reduced proliferation while in contrast, human RPS9-1 siRNA
was inactive in NIH3T3 cells. Cells were counted 72 hours after
transfection and one representative experiment is shown. D)
Relative cell counts for cells depleted of RPS9 in WI38 and WI38-
E6 fibroblasts, SAOS-2 (p53 null) in comparison to U2OS (wt
p53). For each cell line the relative count is established against
siCtrl. E) Depletion of RPL5 and RPL11 marginally inhibits HeLa
cells proliferation as determined by counting all viable cells
48 hours after transfection.
Found at: doi:10.1371/journal.pone.0009578.s001 (8.77 MB TIF)
Figure S2 Nucleolar morphology in RPS9 depleted cells. U2OS
cells (A) and U343MGa Cl2:6 cells (B) were transfected with siCtrl
or siRPS9-1 as indicated. Cells were stained with anti-fibrillarin
antibody (red) and DAPI for counterstaining of DNA.
Found at: doi:10.1371/journal.pone.0009578.s002 (8.96 MB TIF)
Figure S3 Rescue of siRPS9 induced proliferative arrest in
U2OS cells by RPL11, p53 or p21 co-depletion. Combined
silencing of RPL11, p53 or p21 together with RPS9 partially
restores cell proliferation and reverses the flat morphology
phenotype of RPS9 treated U2OS cells.
Found at: doi:10.1371/journal.pone.0009578.s003 (5.89 MB TIF)
Figure S4 Rescue of siRPS9 induced morphological changes in
U343MGa Cl2:6 cells by RPL11, p53 or p21 co-depletion. Cells
depleted of RPS9 frequently display extended cellular processes.
SiCtrl treated cells form tightly packed cuboidal cells in colonies
without process formation. Combined silencing of RPL11, p53 or
p21 restores the parental cellular morphology.
Found at: doi:10.1371/journal.pone.0009578.s004 (5.01 MB TIF)
Figure S5 Morphology of U343MGa Cl2:6 cells depleted of
various ribosomal proteins as indicated.
Found at: doi:10.1371/journal.pone.0009578.s005 (2.67 MB TIF)
Table S1 Antibodies used in study
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